73896-36-3

Usage

Chemical Properties

Yellow solid

InChI:InChI=1/C6H7N3O3/c1-12-5-3-2-4(9(10)11)6(7)8-5/h2-3H,1H3,(H2,7,8)

Upstream product

• 17920-35-3 2-amino-6-methoxypyridine 
• 5446-92-4 2-methoxy-5-nitropyridine 
• 67-56-1 methanol 
• 27048-04-0 2-amino-6-chloro-3-nitropyridine 
• 67-62-9 O-Methylhydroxylamin 
• 7646-85-7 zinc(II) chloride 
• 2402-78-0 2,6-dichloropyridine 
• 16013-85-7 2,6-dicholoro-3-nitropyridine 
• 159603-71-1 t-butyl N-(6-chloro-2-pyridinyl)carbamate 
• 4684-94-0 6-chloropicolinic acid 
• 45644-21-1 6-chloropyridin-2-amine 
• 38533-61-8 2-chloro-6-methoxy-3-nitropyridine 
• 124-41-4 sodium methylate 

Downstream Products

• 28020-38-4 2,3-diamino-6-methoxypyridine 
• 160657-11-4 6-methoxy-3-nitro-2-(1-pyrrolyl)pyridine 
• 211555-30-5 2-amino-3-nitro-6-hydroxypyridine 
• 868539-54-2 5-iodo-6-methoxy-3-nitropyridin-2-amine 
• 84487-04-7 6-bromo-3-nitro-pyridin-2-ylamine 
• 1159824-73-3 6-methoxypyridine-2,3-diamine dihydrochloride 

Relevant academic research and scientific papers

Methods for treating neisseria gonorrhoeae infection with substituted 1,2-dihydro-2A,5,8A-triazaacenaphthylene-3,8-diones

The present invention relates to methods for treating Neisseria Gonorrhoeae infection which comprises administering to a subject in need thereof novel 1,2-dihydro-2a,5,8a-triazaacenaphthylene-3,8-dione compounds: or pharmaceutically acceptable salts thereof and/or corresponding pharmaceutical compositions.

Discovery and analgesic evaluation of 8-chloro-1,4-dihydropyrido[2,3- b ]pyrazine-2,3-dione as a novel potent d -amino acid oxidase inhibitor

A series of 5-azaquinoxaline-2,3-dione derivatives were synthesized and evaluated on d-amino acid oxidase (DAAO) inhibition as potential α-hydroxylactam-based inhibitors. The potent inhibitory activities in vitro suggested that 5-nitrogen could significantly enhance the binding affinity by strengthening relevant hydrogen bond interactions. The analgesic effects of intrathecal and systemic injection of 8-chloro-1,4-dihydropyrido[2,3-b]pyrazine-2,3-dione, a representative molecule of 5-azaquinoxaline-2,3-dione, were investigated in rodents. This research not only confirmed the analgesic effect of the DAAO inhibitors but provided a new class of chemical entities with oral application potential for the treatment of chronic pain and morphine analgesic tolerance.

INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS

The present invention relates to compounds which specifically inhibit bacterial DNA Gyrase and can be used for the treatment of respiratory tract infections.

Diversified synthesis of novel quinoline and dibenzo thiazepine derivatives using known active intermediates

The novel drug development to control resisting infections in conventional drug therapy is a need of today. Few antiulcer relative derivatives developed by approaching convergent synthesis. The derivatives synthesized successfully are dibenzo thiazepine-pyridine (SLN11-SLN15) and benzimidazole-hydroquinoline based derivatives (SLN16-SLN20). It involved the coupling through microwave, sonication and conventional techniques at final step. The efficient technology identified as sonication technique basically time and yield. The reported compounds were structural characterized by elemental analysis and spectral studies such as 1H, 13C NMR and MS.

TRICYCLIC NITROGEN COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS

Tricyclic nitrogen containing compounds and their use as antibacterials.

TRICYCLIC NITROGEN CONTAINING COMPOUNDS AS ANTIBACTERIAL AGENTS

Tricyclic nitrogen containing compounds and their use as antibacterials. Z1and Z2 are independently selected from CH and N.

Methods for Chk2 inhibitor patient selection

The present invention contemplates a method to identify subjects that either have a tumor, or are at risk for tumor development, that are responsive to various inhibitors of an activated-Chk2 protein. Such Chk2 inhibitors may comprise a benzimidazole core structure, and derivatives thereof. Other Chk2 inhibitors may comprise nucleic acids, such as silencing interference RNA's specific for a Chk2 expression. Other Chk2 inhibitors may comprises proteins, such as antibodies. For example, the present invention contemplates that when a Chk2 inhibitor is administered during, or after, ionizing radiation tumor cell apoptosis is increased.

Process for producing 2,3-diamino-6-methoxypyridine

The present invention relates to a novel process for producing 2,3-diamino-6-methxoypyridine. The process comprises neutralizing 2,3-diamino-6-methoxy pyridine dihydrochloride, which, in turn, is prepared by the reduction of 2-amino-6-methoxy-3-nitropyridine. The 2-amino-6-methoxy-3-nitropyridine is further prepared by methoxylation of 2-amino-6-chloro-3-nitropyridine by sodium methoxide in methanol.